title: Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers.
abstract: Controversy still exists regarding the validity of parameters commonly used in the evaluation of prognosis of patients with synovial sarcoma (SS). Forty-nine cases of previously untreated primary SS (23 females and 26 males, ranging in age from 7 to 81, with 31 tumors located in the lower extremity, 8 at the upper extremity and 10 at the trunchus), without regional lymph-node or distant metastases were studied. We investigated the relationship between (flow and image) DNA cytometry, proliferation activity, clinicopathologic parameters, and relapse-free and overall survival of the patients. The prognostic value of gender, age, duration of symptoms, location, compartmentalization, size, adequacy of surgical margins, residual tumor, adjuvant therapy, histologic subtype, extent of necrosis, glandular differentiation, calcification, and extent of hemangiopericytic areas, mitotic rate, amount of mast cells, blood vessel invasion, histologic (UICC and NCI) grades, DNA ploidy, percentage of cells in S and S+G2 phases, PCNA and Ki-67 labeling indices (LI), and TNM (UICC) stage of the tumors, were evaluated by univariate and multivariate (Cox hazard model) analyses. Short duration of symptoms (<12 months), biphasic SS, scarcity of mast cells (<10/10 HPF), high mitotic rate (> or =10/10 HPF), high histologic grade (grade 3), high PCNA-LI (> or =20%), high Ki-67-LI (> or =10%), DNA aneuploidy, and advanced TNM stage (stage III) were features associated with significantly shorter relapse-free and overall 5-year survival rates in the univariate analyses. Scarcity of mast cells, high mitotic rate, or high PCNA-LI were significant predictors of poor survival, in addition to TNM stage in the multivariate analyses. The amount of mast cells was inversely correlated with mitotic rate and PCNA-LI. Scarcity of mast cells, high mitotic rate, or high PCNA-LI are factors associated with poor prognosis, in addition to advanced TNM stage in patients with localized SS.
authors.affiliation: Unit of Molecular Pathology, IPATIMUP, Medical Faculty, Porto, Portugal.
authors.forename: J M
authors.initials: JM
authors.lastname: Lopes
authors.forename: E
authors.initials: E
authors.lastname: Hannisdal
authors.forename: B
authors.initials: B
authors.lastname: Bjerkehagen
authors.forename: O S
authors.initials: OS
authors.lastname: Bruland
authors.forename: H E
authors.initials: HE
authors.lastname: Danielsen
authors.forename: E O
authors.initials: EO
authors.lastname: Pettersen
authors.forename: M
authors.initials: M
authors.lastname: Sobrinho-Simões
authors.forename: J M
authors.initials: JM
authors.lastname: Nesland
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D015415:Biomarkers / Q000032:analysis; D002452:Cell Count; D002455:Cell Division; D002648:Child; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry / Q000706:statistics & numerical data; D006801:Humans; D019044:Image Cytometry / Q000706:statistics & numerical data; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008407:Mast Cells / Q000473:pathology; D008875:Middle Aged; D008940:Mitotic Index / Q000502:physiology; D015999:Multivariate Analysis; D011003:Ploidies; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D013584:Sarcoma, Synovial / Q000235:genetics / Q000401:mortality / Q000473:pathology*
chemical_list: D015415:Biomarkers; D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen